

CLARITY

Controlled evaluation of Angiotensin Receptor Blockers for COVID-19 respiratory disease

Issue 1 | 20 July 2020

Overview

CLARITY will establish if Angiotensin Receptor Blockers (ARBs) can reduce the severity of COVID-19. Pragmatic trial design embedded in routine care to avoid placing additional demands on busy health staff.

Project Updates

Australia

- 4 sites activated (Canterbury, Concord, RPAH, RNSH)
- 6 additional sites initiated, undergoing set up (SGH, POWH, RPA Virtual, Wollongong, Austin Health & Westmead).

India

- Received ethics approval.
- Aiming to activate first site in 2 weeks.
- Starting with 8 sites and increasing.

For any queries relating to the project, please contact:

claritytrial@georgeinstitute.org.au

CLARITY in the News!



Associate Professor Meg Jardine and Professor Carol Pollock from the CLARITY Steering Committee

ABC Radio 'The Health Report' with Norman Swan:

[Click here.](#)

NSW Health: [Click here.](#)

Sydney Morning Herald: [Click here.](#)

Relevant Literature Updates

RECOVERY Trial

- Investigator-initiated, open-label, adaptive platform RCT.
 - 2,104 randomised to 6mg a day of dexamethasone for 10 days and 4,321 randomized to standard of care.
 - Dexamethasone reduces 28-day mortality in COVID-19 patients receiving invasive mechanical ventilation by one third (NNT 8), and by one fifth in patients receiving oxygen without invasive mechanical ventilation (NNT25).
 - Adopted into UK clinical practice.
- ⇒ **Implications for CLARITY:** These findings may impact standard of care. The decision to treat participants with dexamethasone rests with the treating physician.

Meet the Chief Investigators



Associate Professor Meg Jardine

Meg is Program Head of Innovation & Kidney Research at The George Institute for Global Health Australia and Head of Renal Trials at George Clinical.



Professor Vivekanand Jha

Vivek is the Executive Director at The George Institute for Global Health, India and the President of the International Society of Nephrology.

Project Timeline

MAR 2020	Protocol Development	Done
MAY 2020	Study Set up Activities	Done
JUN 2020	First Site Activated	Done
	MRFF Funding Received	Done
JUL 2020	All Sites Activated - Australia	
AUG 2020	All Sites Activated - India	
	DSMB #1	
SEP 2020	DSMB #2	
OCT 2020	DSMB #3	
NOV 2020	Last Participant First Visit	
DEC 2020	All Primary Outcome Data	
JAN 2021	Primary Analysis & Publication	
FEB 2021	Last Participant Last Visit	
MAR 2021	Database Lock & All Sites Closed	
	Secondary Analyses & Publication	

Coming Soon...

Online modules for guidance on ARBs, site initiation training, and more!

